Xcout Intel
Pharma Two B
Pharma Two B Ltd. is a late-clinical stage biopharmaceutical company headquartered in Kiryat Ono, Israel. The company focuses on developing pharmaceutical treatments and therapeutic products for neurological and related medical conditions. It has pursued corporate growth initiatives, including planned public market transactions via mergers.
Subscribe to see Pharma Two B’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Pharma Two B at a glance
Pharma Two B is a pharmaceuticals company headquartered in Israel. Its most recent funding round raised $30M in February 2017.
Pharma Two B funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $30M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Pharma Two B competitors
A few of Pharma Two B's closest competitors — see the full list of competitors and alternatives →
Abital Pharma Pipelines is an incubator in Israel dedicated to advancing life science innovation. The company collaborates with the Naiot incubator to develop drugs targeting the central nervous system.
J2 Bio-Pharma, LLC is a specialty pharmaceutical company that reformulates neurology medications to address unmet medical needs. The company partners with pharmacies, patients, and businesses in the healthcare sector to develop and commercialize therapeutic products.
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Hod Hasharon, Israel. The company focuses on the development and commercialization of treatments for ophthalmic and other serious medical conditions.
Abital Pharma is an Israeli therapeutics company founded in 2012 by Prof. Moussa B. H. Youdim, focusing on the development of original drugs and operating as a life science incubator.
Mapi Pharma is an Israeli pharmaceutical company that develops complex generic and proprietary drug products, with a focus on long-acting injectable formulations. Its products are intended for patients and healthcare providers, and the company works with pharmaceutical partners to develop and commercialize treatments, including therapies for neurological conditions such as multiple sclerosis.
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments. Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
Get Pharma Two B's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Pharma Two B in Xcout Intel
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access